» Articles » PMID: 1901187

Immunogenicity in Adult Males of a Neisseria Meningitidis Group B Vaccine Composed of Polysaccharide Complexed with Outer Membrane Proteins

Overview
Journal Vaccine
Date 1991 Jan 1
PMID 1901187
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Twenty five adult male volunteers were given a vaccine composed of the capsular B polysaccharide non-covalently complexed to serotype 6 outer membrane proteins (OMP) of Neisseria meningitidis. Subjects were divided into three dose groups receiving 50, 100 or 150 micrograms vaccine in aluminium hydroxide in each of three injections spaced 4 weeks apart. Systemic signs/symptoms considered clinically significant were recorded on 6% (4/70) of occasions and were succeeded by withdrawal of two volunteers from the study. Local injection site reactions, mostly mild to moderate, were reported after all vaccinations with one such reaction leading to a third volunteer withdrawing from the study. Geometric mean anti-B responses before immunization and 1 week after the third immunization (9 weeks) were 3.60 and 7.12 micrograms ml-1 in the 50 micrograms group (p less than 0.05) 2.05 and 12.19 micrograms ml-1 in the 100 micrograms group (p less than 0.001), and 3.68 and 14.20 micrograms ml-1 in the 150 micrograms group (p less than 0.001). The anti-B response was predominantly of the IgM isotype and persistence above prevaccination levels was evident for at least 12 months. Anti-type 6 OMP responses were also evidenced with geometric mean multiplicative increases over prevaccination levels at 9 weeks and 6 months of 7.8 and 4.2 for the 50 micrograms group, 11.6 and 5.6 for the 100 micrograms group and 6.8 and 3.4 for the 150 micrograms group. The bulk of this response was of the IgG isotype. Passive protection of mice was achieved with both pre- and post-vaccination (9 weeks; 100 and 150 micrograms groups) pools of sera.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Capsular polysaccharide vaccine for Group B Neisseria meningitidis, Escherichia coli K1, and Pasteurella haemolytica A2.

Robbins J, Schneerson R, Xie G, Hanson L, Ake-Hanson L, Miller M Proc Natl Acad Sci U S A. 2011; 108(44):17871-5.

PMID: 22025709 PMC: 3207679. DOI: 10.1073/pnas.1114489108.


Dynamics of the murine humoral immune response to Neisseria meningitis group B capsular polysaccharide.

Colino J, Outschoorn I Infect Immun. 1998; 66(2):505-13.

PMID: 9453603 PMC: 107935. DOI: 10.1128/IAI.66.2.505-513.1998.


Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

Zollinger W, Moran E, Devi S, Frasch C Infect Immun. 1997; 65(3):1053-60.

PMID: 9038315 PMC: 175087. DOI: 10.1128/IAI.65.3.1053-1060.1997.


Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Devi S, Zollinger W, Snoy P, Tai J, Costantini P, Norelli F Infect Immun. 1997; 65(3):1045-52.

PMID: 9038314 PMC: 175086. DOI: 10.1128/IAI.65.3.1045-1052.1997.


Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design.

Feavers I, Fox A, Gray S, Jones D, Maiden M Clin Diagn Lab Immunol. 1996; 3(4):444-50.

PMID: 8807211 PMC: 170365. DOI: 10.1128/cdli.3.4.444-450.1996.